Beijing, China, September 24, 2025 — In the context of global efforts to strengthen public health systems and improve access to medicines, Gan & Lee Pharmaceuticals. (hereinafter referred to as Gan & Lee, Stock code: 603087.SH) has officially signed a 10-year Technology Transfer and Supply Agreement with Fiocruz¹, a public laboratory under the Brazilian Ministry of Health (MOH), and Biomm, a leading Brazilian biopharmaceutical company. This marks the formal launch of Brazil's Parcerias para o Desenvolvimento Produtivo (PDP) project.

At the same time, Gan & Lee entered into a new Licensing and Supply Agreement with Biomm, securing cumulative orders of no less than RMB 3 billion over ten years, setting a new milestone on the foundation of strategic cooperation.

Addressing People's Needs: Tackling Brazil's Insulin Supply Gap

As a core initiative to enhance the resilience of Brazil's public health system, the PDP project aims to introduce advanced international technologies while engaging local industries to fundamentally resolve supply gaps and improve access to essential medicines. Diabetes, one of the world's most prevalent chronic diseases, makes insulin an indispensable treatment option. For Brazil, the largest country in Latin America by population, ensuring stable insulin supply is a particularly urgent priority. The tripartite collaboration focuses on this pressing public health need, with technology cooperation as the driving force, building a localized insulin manufacturing system and securing stable supply for patients.

Complementary Roles: Building a "Technology + Localization" Cooperation Loop

Each partner will play a distinct role to form a closed-loop model of "technology transfer-local production-long-term procurement."

Gan & Lee bring over two decades of deep expertise in insulin R&D, manufacturing, and quality control, providing comprehensive technical support for localized insulin production in Brazil.

Biomm, leveraging its in-depth understanding of local regulatory frameworks, healthcare systems, and market dynamics, ensures rapid compliance and market entry. 

Fiocruz, as both the technology recipient and the ultimate purchaser under the Brazilian Health Regulatory Agency (Anvisa), commits to long-term procurement over the next 10 years, adhering to the agreed-upon prices and volume specifications.

This three-way synergy will significantly accelerate the accessibility and affordability of high-quality insulin in Brazil.

Phased Implementation: From Emergency Supply to Full Independence

The cooperation will be advanced in phases to achieve Brazil's long-term goal of insulin self-sufficiency:

Initial phase: Gan & Lee will prioritize the supply of insulin glargine injection to help address urgent clinical demand in Brazil.

Mid-term: Gan & Lee will transfer insulin glargine technology to Fiocruz, while continuing to supply both finished insulin glargine products and drug substances to Biomm. Biomm will conduct local filling of insulin glargine injection and deliver it, together with compatible pen injectors, to Fiocruz.

Long-term: The three parties will collaborate in professional talent development and the establishment of full-scale quality control systems to ensure that locally produced insulin meets international standards of quality, safety, and efficacy — ultimately realizing Brazil's goal of insulin self-sufficiency.

Empowering China-Brazil Collaboration: A New Chapter in Biopharmaceutical Partnership

Gan & Lee stands as the first Chinese pharmaceutical company to participate in Brazil's PDP project. The joint proposal it developed with its partners succeeded in breaking the dominance of multinational pharmaceutical corporations and was ultimately selected as the sole winning project. This achievement not only serves as a model of technological sharing under the Belt and Road Initiative but also signifies a leap from participation to leadership for Chinese pharmaceutical enterprises in international public health cooperation — underscoring Gan & Lee's commitment to global healthcare governance.

About the PDP Program

The PDP program is a cornerstone initiative of Brazil's National Public Health System. Its core objective is to secure the long-term and stable supply of essential medicines by strengthening the country's healthcare infrastructure. Under the program's mechanism, Brazil's public healthcare system commits to long-term procurement in exchange for multinational pharmaceutical companies transferring advanced product technologies, thereby establishing a complete local manufacturing ecosystem in Brazil.

Notes

1. Founded in 1900, Fiocruz is the only public laboratory directly under the Brazilian Ministry of Health (MOH).

About Gan & Lee

Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin^®), fast-acting lispro injection (Prandilin™), fast-acting aspart injection (Rapilin^®), mixed protamine zinc lispro injection (25R) (Prandilin™25), aspart 30 injection (Rapilin^®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^®30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^®).

In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked  first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine^®) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee’s competitiveness in both international and domestic markets.

In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.